Lumature Wealth Partners, LLC Alnylam Pharmaceuticals, Inc. Transaction History

Lumature Wealth Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$120.42 - $169.29 $4,816 - $6,771	-40 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$127.18 - $173.91 $7,630 - $10,434	-60 Reduced 60.0%	40 $7,000
Q4 2021 Feb 10, 2022	SELL	$159.56 - $209.29 $7,978 - $10,464	-50 Reduced 33.33%	100 $17,000
Q3 2021 Oct 29, 2021	SELL	$169.75 - $207.73 $10,354 - $12,671	-61 Reduced 28.91%	150 $28,000
Q2 2021 Aug 10, 2021	BUY	$128.63 - $176.89 $1,286 - $1,768	10 Added 4.98%	211 $36,000
Q1 2021 May 11, 2021	SELL	$126.83 - $175.69 $295,006 - $408,654	-2,326 Reduced 92.05%	201 $28,000
Q4 2020 Feb 08, 2021	BUY	$122.97 - $147.0 $310,745 - $371,469	2,527 New	2,527 $328,000

645

109M

1.28M

1.22M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.7B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Lumature Wealth Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Lumature Wealth Partners, LLC with notifications on news.